Sugi Predict

Sugi Predict / Compounds / Chlorindanol

Chlorindanol

Chlorindanol

SCHEMBL615288

Oc1ccc(Cl)c2c1CCC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 2/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ BCL2L1 Q07817 1/20 0.40
▸ BAD Q92934 1/20 0.40
▸ NISCH Q9Y2I1 2/20 0.38
▸ AR P10275 1/20 0.37
▸ HSD17B10 Q99714 4/20 0.36
▸ ALDH1A1 P00352 4/20 0.36
▸ TSHR P16473 2/20 0.36
▸ TDP1 Q9NUW8 2/20 0.36
▸ HTR2A P28223 1/20 0.35
▸ HTR2C P28335 1/20 0.35
▸ HTR2B P41595 1/20 0.35
▸ MAPT P10636 2/20 0.33
▸ HTT P42858 2/20 0.33
▸ HPGD P15428 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chlorindanol SCHEMBL29929703 1.00 CYP3A4 (0.42) CYP3A4MAPK1BCL2L1BADNISCH
SCHEMBL10773279 0.95 BCL2L1 (0.45) CYP3A4MAPK1BCL2L1BADNISCH
SCHEMBL10802712 0.84 BCL2L1 (0.50) MAPK1BCL2L1BADARHSD17B10
SCHEMBL8909616 0.80 HTR2C (0.50) CYP3A4MAPK1HTR2AHTR2CHTR2B
SCHEMBL3283307 0.79 BCL2L1 (0.56) CYP3A4MAPK1BCL2L1BADAR
SCHEMBL8910486 0.77 ADRA2A (0.55) NPSR1
SCHEMBL31104321 0.76 BRD4 (0.40) CYP3A4MAPK1BCL2L1BADALDH1A1
SCHEMBL1008430 0.73 MAOA (0.44) CYP3A4MAPK1BCL2L1BADAR
SCHEMBL806282 0.73 NISCH (0.42) CYP3A4NISCHALDH1A1HTR2AHTR2C
SCHEMBL20597241 0.73 PDE7A (0.43) CYP3A4MAPK1BCL2L1BADHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 — — US claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 — — US claimed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 — — WO claimed
WO-2022182523-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2022-09-01 — — WO claimed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 — — WO claimed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 — — WO claimed
US-10377779-B2 Carbonate prodrugs and methods of using the same ACORDA THERAPEUTICS, INC. (US) 2019-08-13 — — US claimed
CN-108409543-A A kind of preparation process of 7- chloro-4-hydroxyls dihydroindene 遵义医学院附属医院 2018-08-17 — — CN claimed
US-20180086778-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME NEUROGESX, INC. 2018-03-29 — — US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
EP-1317304-B1 SLOW RELEASE PHARMACEUTICAL PREPARATION AND METHOD OF ADMINISTERING SAME PALMAYA PTY LTD (AU) 2011-04-27 — — EP claimed
EP-2291084-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME Neurogesx, Inc. (US) 2011-03-09 — — EP claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
WO-2009143297-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME NEUROGESX, INC. (US) 2009-11-26 — — WO claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
US-20050025847-A1 Microbicidal compositions and method of use PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (US) 2005-02-03 — — US claimed
WO-2004075854-A2 MICROBICIDAL COMPOSITIONS AND METHOD OF USE PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (US) 2004-09-10 — — WO claimed
US-6309669-B1 Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY 2001-10-30 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB CYP3A4 3571/4885MAPK1 3646/4885BCL2L1 964/4885
US-10377779-B2 Carbonate prodrugs and methods of using the same CA6, CA7, CA4 CYP3A4 135/4885MAPK1 3559/4885BCL2L1 4590/4885
US-20180086778-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME CA6, CA7, CA4 CYP3A4 135/4885MAPK1 3559/4885BCL2L1 4590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.